The Emergence Of Deep-Tech Start-Ups
LIVELAW NEWS NETWORK
27 Jan 2023 9:04 AM GMT
![The Emergence Of Deep-Tech Start-Ups The Emergence Of Deep-Tech Start-Ups](https://www.livelaw.in/h-upload/2023/01/27/750x450_455904-vis-legis.webp)
Technology and Science are ever changing and progressing. The basic technologies of today were once an ambitious vision of a past scholar/inventor. Right from the vaccine for the deadly Tuberculosis which took around thirteen years to be developed, to the vaccine for the novel coronavirus being developed in a record-breaking period of approximately one year, science has progressed. Such historic achievement can only be accomplished by the amalgamation of science and technology. Deep Tech is where the science meets technology for the betterment of mankind, it is like building a finer future in the field of medicine and sanitation industry with the assistance of superior technology.
The emergence of new variants of diseases accompanied by the lack or scarcity of medical data with regards to the remedies over it, has led to a drastic rise in market demand for such Biotechnology Research Companies, which is attracting the attention and opening the flood gates of opportunity for investments into such start-ups that has objectives of creating affordable and scalable PCR and genomics solutions for labs using their innovative reagent technology.
D-NOME Private Limited (“D-Nome”) is one such start-up which was founded in the year 2021 by Ms. Divya Sriram & Mr. Sujoy Deb with an aim to transform molecular diagnostics with an innovative strive to bring premium diagnostics affordable and accessible to all as well as to bring plug-and-play bio-technologies to life and solve the problems in the diagnostics and healthcare sector. D-NOME is democratizing molecular diagnostics leveraging its proprietary deviceless room-temperature D-LAMP platform technology based on synthetic biology- enabling rapid, scalable and point-of-care diagnostics. LAMP technology is a low-cost alternative to PCR technology and has the potential to be used at the point of care. While PCR needs to incorporate controlled heating cycles for amplification, DLAMP, D-NOME’s proprietary technology, enables amplification of DNA/RNA at room temperature without the use of any complex machinery.
The emergence of new variants of diseases accompanied by the lack or scarcity of medical data with regards to the remedies over it, has led to a drastic rise in market demand for such Biotechnology Research Companies, which is attracting the attention and opening the flood gates of opportunity for investments by venture capital firms. D-NOME has itself raised over approximately rupees eleven crores from variety of investors to fund its objective of creating affordable and scalable PCR and genomics solutions for labs using their innovative reagent technology. Start-ups while raising funds from the Investors to grow, require financial and legal advice at every stage of their business right from the Term Sheets with Investors till the execution of Definitive Agreements with Investors and also helping the start-ups in protecting their business and monetize their ideas and to ensure the smooth functioning of business and so on. D-NOME has raised funds from various venture capital firms including 8X Ventures, 3i Partners, Let’s Venture Angel Fund, Ankur Capital and many others with the help of the team of Vis Legis Law Practice, Advocates lead by the Founder and Managing Partner Mr. Rahul Hingmire and Partner Mr. Harshvardhan Deshmukh, along with the Associate Partner Mr. Chirag Bhavsar and Attorney Ms. Aditi Hambarde in successfully raising funds in working towards building an effective disease diagnostics tool utilizing synthetic biology and genomics, the current fundraise takes us to the next milestone closer to our vision of bringing affordable personalized diagnostics to all.